Oral Contraceptives and Breast Cancer PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Oral Contraceptives and Breast Cancer PDF full book. Access full book title Oral Contraceptives and Breast Cancer by Institute of Medicine. Download full books in PDF and EPUB format.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309044936
Category : Medical
Languages : en
Pages : 196
Get Book Here
Book Description
At least 10.7 million American women use oral contraceptives (OCs). The potential connection with breast cancer has caused concern among these OC users and uncertainty among many of their physicians. This new volume offers the most up-to-date information available on this critical topic. While the best available knowledge does not support any fundamental change in clinical practice with respect to the use of OCs, this book offers specific recommendations for more research to fully resolve the relationship between OCs and breast cancer. Noting consumer confusion, the volume includes a concise summary of benefits, risks, and other practical information for contraceptive users and their doctors. The volume presents current data on changes in patterns of OC use, differences in risk at different ages, the benefits of OCs, and more. Oral Contraceptives and Breast Cancer will be important reading for obstetricians/gynecologists and other health professionals, their patients who use OCs, contraceptive manufacturers, women's health advocates, policymakers, and researchers.
Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309044936
Category : Medical
Languages : en
Pages : 196
Get Book Here
Book Description
At least 10.7 million American women use oral contraceptives (OCs). The potential connection with breast cancer has caused concern among these OC users and uncertainty among many of their physicians. This new volume offers the most up-to-date information available on this critical topic. While the best available knowledge does not support any fundamental change in clinical practice with respect to the use of OCs, this book offers specific recommendations for more research to fully resolve the relationship between OCs and breast cancer. Noting consumer confusion, the volume includes a concise summary of benefits, risks, and other practical information for contraceptive users and their doctors. The volume presents current data on changes in patterns of OC use, differences in risk at different ages, the benefits of OCs, and more. Oral Contraceptives and Breast Cancer will be important reading for obstetricians/gynecologists and other health professionals, their patients who use OCs, contraceptive manufacturers, women's health advocates, policymakers, and researchers.
Author: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
Publisher: World Health Organization
ISBN:
Category : Medical
Languages : en
Pages : 692
Get Book Here
Book Description
Evaluates evidence for an increased risk of cancer in women using combined oral contraceptives, progestogen-only hormonal contraceptives, post-menopausal estrogen therapy, and post-menopausal estrogen-progestogen therapy. Although the carcinogenicity of these preparations has been extensively investigated, the book stresses the many complex methodological issues that must be considered when interpreting findings and weighing results. Evidence of an association between use of these preparations and positive effects on health, including a reduced risk of some cancers, is also critically assessed. The first and most extensive monograph evaluates evidence of an association between the use of combined oral contraceptives and cancer at nine sites. Concerning breast cancer, the evaluation concludes that, even if the association is causal, the excess risk for breast cancer associated with patterns of use that are typical today is very small. Studies of predominantly high-dose preparations found an increased risk of hepatocellular carcinoma in the absence of hepatitis viruses. Citing these findings, the evaluation concludes that there is sufficient evidence in humans for the carcinogenicity of combined oral contraceptives. The evaluation also found sufficient evidence for the carcinogenicity of some, but not all, combined preparations in animals. Combined oral contraceptives were classified as carcinogenic to humans. The evaluation also cites conclusive evidence that these agents have a protective effect against cancers of the ovary and endometrium. Progestogen-only contraceptives are evaluated in the second monograph, which considers the association with cancer at six sites. The evaluation found no evidence of an increased risk for breast cancer. Although the evaluation found sufficient evidence in animals for the carcinogenicity of medroxyprogesterone acetate, evidence for the carcinogenicity of progestogen-only contraceptives in humans was judged inadequate. Progestogen-only contraceptives were classified as possibly carcinogenic to humans. The third monograph, on post-menopausal estrogen therapy, considers evidence of an association with cancer at eight sites. Findings from a large number of epidemiological studies indicate a small increase in the risk of breast cancer in women who have used these preparations for five years or more. Studies consistently show an association between use of post-menopausal estrogen therapy and an increased risk for endometrial cancer. Data on the association with other cancers were either inconclusive or suggested no effect on risk. The evaluation concludes that post-menopausal estrogen therapy is carcinogenic to humans. The final monograph evaluates the association between the use of post-menopausal estrogen-progestogen therapy and cancer at four sites. The evaluation of limited data on breast cancer found an increased relative risk observed with long-term use. Data were judged insufficient to assess the effects of past use and of different progestogen compounds, doses, and treatment schedules. For endometrial cancer, the evaluation found an increase in risk relative to non-users when the progestogen was added to the cycle for 10 days or fewer. Post-menopausal estrogen-progestogen therapy was classified as possibly carcinogenic to humans. Concerning post-menopausal therapy in general, the book notes that evidence of carcinogenic risks must be placed in perspective of potential benefits. The prevention of osteoporotic fractures is cited as the best-established benefit. Evidence also suggests that estrogen prevents heart disease and may prevent memory loss and dementia.
Author: Chris Kahlenborn
Publisher: One More Soul
ISBN: 9780966977738
Category : Abortion
Languages : en
Pages : 404
Get Book Here
Book Description
Author: R.D. Mann
Publisher: CRC Press
ISBN: 9781850702825
Category : Medical
Languages : en
Pages : 426
Get Book Here
Book Description
A collection of the proceedings presented at the Royal Society of Medicine by American and European researchers involved in longterm studies on oral contraceptives. Topics include reviews of case-control studies on contraceptive use before the age of 25 or the first full-term pregnancy.
Author: Melinda Wallach
Publisher:
ISBN: 9780965174527
Category : Medical
Languages : en
Pages : 308
Get Book Here
Book Description
Author: National Research Council
Publisher: National Academies Press
ISBN: 0309040965
Category : Medical
Languages : en
Pages : 172
Get Book Here
Book Description
These four papers supplement the book Contraception and Reproduction: Health Consequences for Women and Children in the Developing World by bringing together data and analyses that would otherwise be difficult to obtain in a single source. The topics addressed are an analysis of the relationship between maternal mortality and changing reproductive patterns; the risks and benefits of contraception; the effects of changing reproductive patterns on infant health; and the psychosocial consequences to women of controlled fertility and contraceptive use.
Author: World Health Organization. Reproductive Health and Research
Publisher: World Health Organization
ISBN: 9241562846
Category : Medical
Languages : en
Pages : 144
Get Book Here
Book Description
This document is one of two evidence-based cornerstones of the World Health Organization's (WHO) new initiative to develop and implement evidence-based guidelines for family planning. The first cornerstone, the Medical eligibility criteria for contraceptive use (third edition) published in 2004, provides guidance for who can use contraceptive methods safely. This document, the Selected practice recommendations for contraceptive use (second edition), provides guidance for how to use contraceptive methods safely and effectively once they are deemed to be medically appropriate. The recommendations contained in this document are the product of a process that culminated in an expert Working Group meeting held at the World Health Organization, Geneva, 13-16 April 2004.
Author:
Publisher:
ISBN:
Category : Breast
Languages : en
Pages : 2
Get Book Here
Book Description
Author: Afsaneh Golshani
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Breast cancer is the most common cancer in women worldwide. Studies have linked modifiable and non-modifiable risk factors to an increased diagnosis of breast cancer; however, having these risk factors does not mean the person will get the disease. Oral contraceptive use, among many other modifiable risk factors, have raised questions about the increase in risk it might bear in women of reproductive age. The oral contraceptive pill is currently the fourth most common contraceptive method worldwide used by over 150 million women daily. Recent data has shown evidence that use of oral contraceptives may have an increased risk of breast and cervical cancers, while risks of endometrial, ovarian, and colorectal cancers are reduced. This systematic review evaluated the literature for qualitative themes pertaining to the use of oral contraceptives with newer formulations and the impact on breast cancer risk. The aim of this research was to understand usage of birth control pills, length of use, and the specific formulation.
Author:
Publisher: World Health Organization
ISBN: 9241563885
Category : Business & Economics
Languages : en
Pages : 130
Get Book Here
Book Description
Medical Eligibility Criteria for Contraceptive Use reviews the medical eligibility criteria for use of contraception, offering guidance on the safety and use of different methods for women and men with specific characteristics or known medical conditions. The recommendations are based on systematic reviews of available clinical and epidemiological research. It is a companion guideline to Selected Practice Recommendations for Contraceptive Use. Together, these documents are intended to be used by policy-makers, program managers, and the scientific community to support national programs in the preparation of service delivery guidelines. The fourth edition of this useful resource supersedes previous editions, and has been fully updated and expanded. It includes over 86 new recommendations and 165 updates to recommendations in the previous edition. Guidance for populations with special needs is now provided, and a new annex details evidence on drug interactions from concomitant use of antiretroviral therapies and hormonal contraceptives. To assist users familiar with the third edition, new and updated recommendations are highlighted. Everyone involved in providing family planning services and contraception should have the fourth edition of Medical Eligibility Criteria for Contraceptive Use at hand.
